bachelorThesis
Identification of Promiscuous T cell Epitopes on Mayaro virus structural proteins using immunoinformatics, molecular modeling, and QM:MM approaches
Registro en:
2016080660
SILVA, Maria Karolaynne da. Identification of Promiscuous T cell Epitopes on Mayaro virus structural proteins using immunoinformatics, molecular modeling, and QM:MM approaches. 2021. 30 f. Trabalho de Conclusão de Curso (Graduação em Farmácia) - Departamento de Farmácia, Universidade Federal do Rio Grande do Norte, Natal, 2021.
Autor
Silva, Maria Karolaynne
Resumen
Capes, CNPq The Mayaro virus (MAYV) belongs to genus Alphavirus (family Togaviridae) and has been
reported in several countries, especially in tropical regions of America. Due to its outbreaks
and potential lack of medication, an effective vaccine formulation is strongly required. This
study aimed to predict promiscuous T cell epitopes from structural polyproteins of MAYV
using an immunoinformatics approach. For this purpose, consensus sequences were used to
identify short protein sequences capable of binding to MHC class I and class II alleles. Our
analysis pointed out 4 MHC-I/TCD8+ and 21 MHC-II/TCD4+ epitopes on capside (1;3), E1
(2;5), E2 (1;10), E3 (0;2), and 6K (0;1) proteins. These predicted epitopes were characterized by
high antigenicity, immunogenicity, conservancy, non-allergenic, non-toxic, and good population
coverage rate values for North and South American geographical areas. Afterwards, we used
the crystal structure of human toll-like receptor 3 (TLR3) ectodomain as a template to predict,
through docking essays, the placement of a vaccine prototype at the TLR3 receptor binding site.
Finally, classical and quantum mechanics/molecular mechanics (QM:MM) computations were
employed to improve the quality of docking calculations, with the QM part of the simulations
being accomplished by using the density functional theory (DFT) formalism. These results
provide important insights into the advancement of diagnostic platforms, the development of
vaccines, and immunotherapeutic interventions. 2022-03-10